https://doi.org/10.1016/j.ijpx.2026.100588
Pramod Kumar1, Ashesh Chakraborty1, Elias Richter1, Lin Yang1, Andreas Schröppel1, Coralie Mergault2,3, Larissa Rothkirch Née Knüppel4, Frank Jaschinski4, Marion Blayac1, Rita Vanbever5, Laurent Plantier2,3,6, Nathalie Heuzé-Vourch2,3, Otmar Schmid1
1Institute of Lung Health and Immunity, Comprehensive Pneumology Center (CPC-M) with the CPC-M bioArchive, Ludwig-Maximilians-Universität München and Helmholtz Munich, Member of the German Center for Lung Research (DZL), Germany
2Centre d’Etudes des Pathologies Respiratoires / Inserm UMR1100, Tours, France
3Université de Tours, Tours, France
4Secarna Pharmaceuticals GmbH & Co. KG, Planegg, Germany
5Université catholique de Louvain, Louvain Drug Research Institute, Advanced Drug Delivery & Biomaterials, Belgium
6CHRU de Tours, Service de Pneumologie et Explorations Fonctionnelles Respiratoires, Tours, France
The development of inhaled nucleic acid therapeutics is rapidly advancing, yet physiologically relevant in vitro testing remains a major challenge. A recently published study demonstrates how precise microliter-scale aerosol delivery can significantly improve the translational relevance of preclinical testing for inhaled antisense oligonucleotides (ASOs). Using the VITROCELL Cloud MAX technology, researchers achieved highly controlled deposition of extremely small aerosol volumes onto air-liquid interface (ALI) cell cultures and revealed previously underappreciated pharmacokinetic effects associated with realistic aerosol dosing. The findings highlight the importance of exposure technology in the development of next-generation inhaled biologics and strengthen the role of advanced ALI exposure systems in inhalation toxicology and drug development.
